Article PDF first page preview

First page of Limited progression of nuclear sclerosis after lens sparing vitrectomy in proliferative diabetic retinopathy eyes: a real-world investigation with Scheimpflug lens densitometry

Background: To objectively investigate the progression of lens nuclear sclerosis after lens spearing pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDR). Methods: Comparison of Pentacam HR® Scheimpflug imaging-based lens densitometry of eyes with PDR-associated tractive retinal detachment (Study Group) and nondiabetic eyes with rhegmatogenous retinal detachment (Control Group) after lens-sparing PPV.rp Results: Fifty-nine eyes of 55 subjects treated with gas (GT; 29 eyes in the Study and 30 in the control group; Mean follow-up: 381.41 [±309.17] days) and 42 eyes of 41 subjects treated with silicone oil tamponade (SOT; 10 eyes in the Study and 32 in the control group; mean follow-up: 326.50 [±239.59] days) were included. The prediction model for postoperative lens densitometry progression indicated that the increase in lens densitometry was lower in the study group than in the control group, regardless of the type of tamponade used. A second adjusted prediction model, including only age and baseline lens densitometry-matched eyes, further confirmed that the study group experienced a lower increase in lens densitometry in both SOT and GT cases than the control group. Conclusions: The increase in lens nuclear sclerosis is more pronounced in nondiabetic eyes than in those with PDR after lens-sparing vitrectomy. These findings support the hypothesis that ischemia in PDR may protect against the development of nuclear cataracts following PPV.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.